COPENHAGEN, May 13 (Reuters) - The Danish medicines agency on Monday warned of a supply shortage for two separate doses of Novo Nordisk's hugely popular weight loss drug Wegovy due to increasing demand. (Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
919.7 DKK | -0.98% | +1.82% | +31.74% |
May. 27 | Novo Nordisk: share buybacks continue | CF |
May. 25 | Wegovy users have less kidney-related health problems, analysis of Novo study finds | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.74% | 594B | |
+38.51% | 727B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Denmark faces Wegovy shortage due to rising demand, medicines agency says